Intrinsic value of Advaxis - ADXS

Previous Close

$2.93

  Intrinsic Value

$0.33

stock screener

  Rating & Target

str. sell

-89%

Previous close

$2.93

 
Intrinsic value

$0.33

 
Up/down potential

-89%

 
Rating

str. sell

We calculate the intrinsic value of ADXS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  200.00
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  12
  12
  13
  13
  13
  14
  14
  15
  15
  16
  16
  17
  18
  18
  19
  20
  21
  22
  23
  24
  25
  26
  27
  28
  30
  31
  33
  34
  36
  38
  39
Variable operating expenses, $m
 
  49
  50
  51
  53
  54
  56
  58
  60
  62
  65
  67
  70
  73
  76
  79
  83
  87
  90
  95
  99
  103
  108
  113
  119
  124
  130
  137
  143
  150
  157
Fixed operating expenses, $m
 
  68
  69
  71
  73
  75
  77
  78
  80
  82
  84
  87
  89
  91
  93
  96
  98
  100
  103
  106
  108
  111
  114
  116
  119
  122
  125
  129
  132
  135
  138
Total operating expenses, $m
  111
  117
  119
  122
  126
  129
  133
  136
  140
  144
  149
  154
  159
  164
  169
  175
  181
  187
  193
  201
  207
  214
  222
  229
  238
  246
  255
  266
  275
  285
  295
Operating income, $m
  -99
  -104
  -107
  -110
  -112
  -115
  -119
  -122
  -126
  -129
  -133
  -137
  -141
  -146
  -150
  -155
  -160
  -165
  -171
  -176
  -182
  -188
  -195
  -202
  -208
  -216
  -223
  -231
  -239
  -248
  -257
EBITDA, $m
  -98
  -103
  -106
  -109
  -111
  -114
  -118
  -121
  -124
  -128
  -132
  -136
  -140
  -144
  -149
  -153
  -158
  -164
  -169
  -174
  -180
  -186
  -193
  -199
  -206
  -213
  -220
  -228
  -236
  -245
  -253
Interest expense (income), $m
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
Earnings before tax, $m
  -98
  -104
  -106
  -109
  -112
  -115
  -118
  -122
  -125
  -129
  -133
  -137
  -141
  -145
  -150
  -155
  -160
  -165
  -171
  -176
  -182
  -189
  -195
  -202
  -209
  -216
  -224
  -232
  -240
  -249
  -257
Tax expense, $m
  -5
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -93
  -104
  -106
  -109
  -112
  -115
  -118
  -122
  -125
  -129
  -133
  -137
  -141
  -145
  -150
  -155
  -160
  -165
  -171
  -176
  -182
  -189
  -195
  -202
  -209
  -216
  -224
  -232
  -240
  -249
  -257

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  70
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  94
  24
  25
  26
  26
  27
  28
  29
  30
  31
  32
  34
  35
  36
  38
  40
  41
  43
  45
  47
  49
  52
  54
  57
  59
  62
  65
  68
  72
  75
  79
Adjusted assets (=assets-cash), $m
  24
  24
  25
  26
  26
  27
  28
  29
  30
  31
  32
  34
  35
  36
  38
  40
  41
  43
  45
  47
  49
  52
  54
  57
  59
  62
  65
  68
  72
  75
  79
Revenue / Adjusted assets
  0.500
  0.500
  0.520
  0.500
  0.500
  0.519
  0.500
  0.517
  0.500
  0.516
  0.500
  0.500
  0.514
  0.500
  0.500
  0.500
  0.512
  0.512
  0.511
  0.511
  0.510
  0.500
  0.500
  0.491
  0.508
  0.500
  0.508
  0.500
  0.500
  0.507
  0.494
Average production assets, $m
  11
  11
  11
  11
  12
  12
  12
  13
  13
  14
  14
  15
  15
  16
  17
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
  27
  29
  30
  31
  33
  34
Working capital, $m
  60
  -10
  -10
  -11
  -11
  -11
  -12
  -12
  -13
  -13
  -13
  -14
  -15
  -15
  -16
  -17
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -30
  -31
  -33
Total debt, $m
  0
  -18
  -17
  -17
  -16
  -16
  -15
  -14
  -13
  -12
  -11
  -10
  -8
  -7
  -6
  -4
  -3
  -1
  1
  3
  4
  7
  9
  11
  13
  16
  19
  21
  24
  28
  31
Total liabilities, $m
  39
  22
  23
  23
  24
  24
  25
  26
  27
  28
  29
  30
  32
  33
  34
  36
  37
  39
  41
  43
  44
  47
  49
  51
  53
  56
  59
  61
  64
  68
  71
Total equity, $m
  54
  2
  3
  3
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  7
  7
  7
  8
  8
Total liabilities and equity, $m
  93
  24
  26
  26
  27
  27
  28
  29
  30
  31
  32
  33
  36
  37
  38
  40
  41
  43
  46
  48
  49
  52
  54
  57
  59
  62
  66
  68
  71
  76
  79
Debt-to-equity ratio
  0.000
  -7.340
  -6.970
  -6.570
  -6.150
  -5.700
  -5.240
  -4.770
  -4.300
  -3.820
  -3.350
  -2.880
  -2.420
  -1.960
  -1.510
  -1.080
  -0.660
  -0.250
  0.150
  0.540
  0.910
  1.270
  1.610
  1.940
  2.260
  2.570
  2.860
  3.140
  3.410
  3.670
  3.920
Adjusted equity ratio
  -0.667
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -93
  -104
  -106
  -109
  -112
  -115
  -118
  -122
  -125
  -129
  -133
  -137
  -141
  -145
  -150
  -155
  -160
  -165
  -171
  -176
  -182
  -189
  -195
  -202
  -209
  -216
  -224
  -232
  -240
  -249
  -257
Depreciation, amort., depletion, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
Funds from operations, $m
  -90
  -103
  -105
  -108
  -111
  -114
  -117
  -120
  -124
  -127
  -131
  -135
  -140
  -144
  -148
  -153
  -158
  -163
  -169
  -174
  -180
  -186
  -193
  -199
  -206
  -214
  -221
  -229
  -237
  -245
  -254
Change in working capital, $m
  -13
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
Cash from operations, $m
  -77
  -103
  -105
  -108
  -110
  -113
  -117
  -120
  -123
  -127
  -131
  -135
  -139
  -143
  -148
  -153
  -158
  -163
  -168
  -174
  -179
  -185
  -192
  -198
  -205
  -212
  -220
  -228
  -236
  -244
  -253
Maintenance CAPEX, $m
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
New CAPEX, $m
  -5
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
Cash from investing activities, $m
  -12
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -5
  -5
Free cash flow, $m
  -89
  -104
  -106
  -109
  -112
  -115
  -118
  -121
  -125
  -129
  -133
  -137
  -141
  -145
  -150
  -155
  -160
  -165
  -171
  -176
  -182
  -189
  -195
  -202
  -209
  -216
  -224
  -232
  -240
  -248
  -257
Issuance/(repayment) of debt, $m
  0
  -18
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
Issuance/(repurchase) of shares, $m
  1
  123
  106
  109
  112
  115
  118
  122
  125
  129
  133
  137
  141
  146
  150
  155
  160
  165
  171
  177
  183
  189
  195
  202
  209
  216
  224
  232
  240
  249
  258
Cash from financing (excl. dividends), $m  
  1
  105
  107
  110
  113
  116
  119
  123
  126
  130
  134
  138
  142
  147
  151
  156
  162
  167
  173
  179
  185
  191
  197
  204
  211
  219
  227
  235
  243
  252
  261
Total cash flow (excl. dividends), $m
  -89
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  4
  4
Retained Cash Flow (-), $m
  65
  -123
  -106
  -109
  -112
  -115
  -118
  -122
  -125
  -129
  -133
  -137
  -141
  -146
  -150
  -155
  -160
  -165
  -171
  -177
  -183
  -189
  -195
  -202
  -209
  -216
  -224
  -232
  -240
  -249
  -258
Prev. year cash balance distribution, $m
 
  70
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -52
  -106
  -108
  -111
  -114
  -117
  -121
  -124
  -128
  -132
  -136
  -140
  -144
  -149
  -153
  -158
  -164
  -169
  -175
  -180
  -186
  -193
  -199
  -206
  -214
  -221
  -229
  -237
  -245
  -254
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  -50
  -97
  -94
  -92
  -89
  -85
  -81
  -78
  -73
  -69
  -64
  -60
  -55
  -50
  -45
  -40
  -36
  -31
  -27
  -23
  -19
  -16
  -13
  -11
  -8
  -6
  -5
  -4
  -3
  -2
Current shareholders' claim on cash, %
  100
  50.0
  2.4
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.


Warning: Division by zero in /home3/webhub/public_html/x-fin.com/stocks/a-inc/ratios.php on line 28

Warning: Division by zero in /home3/webhub/public_html/x-fin.com/stocks/a-inc/ratios.php on line 30

Warning: Division by zero in /home3/webhub/public_html/x-fin.com/stocks/a-inc/ratios.php on line 32

Warning: Division by zero in /home3/webhub/public_html/x-fin.com/stocks/a-inc/ratios.php on line 34

Warning: Division by zero in /home3/webhub/public_html/x-fin.com/stocks/a-inc/ratios.php on line 36

FINANCIAL RATIOS  of  Advaxis (ADXS)

Valuation Ratios
P/E Ratio -1.3
Price to Sales 10.1
Price to Book 2.2
Price to Tangible Book
Price to Cash Flow -1.6
Price to Free Cash Flow -1.5
Growth Rates
Sales Growth Rate 200%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 25%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0.2
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -70.7%
Ret/ On Assets - 3 Yr. Avg. -62.6%
Return On Total Capital -107.5%
Ret/ On T. Cap. - 3 Yr. Avg. -79.7%
Return On Equity -107.5%
Return On Equity - 3 Yr. Avg. -79.7%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -808.3%
EBITDA Margin - 3 Yr. Avg. -902.8%
Operating Margin -825%
Oper. Margin - 3 Yr. Avg. -908.3%
Pre-Tax Margin -816.7%
Pre-Tax Margin - 3 Yr. Avg. -905.6%
Net Profit Margin -775%
Net Profit Margin - 3 Yr. Avg. -875%
Effective Tax Rate 5.1%
Eff/ Tax Rate - 3 Yr. Avg. 3.9%
Payout Ratio 0%

ADXS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ADXS stock intrinsic value calculation we used $12 million for the last fiscal year's total revenue generated by Advaxis. The default revenue input number comes from 2017 income statement of Advaxis. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ADXS stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ADXS is calculated based on our internal credit rating of Advaxis, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Advaxis.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ADXS stock the variable cost ratio is equal to 400%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $66 million in the base year in the intrinsic value calculation for ADXS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Advaxis.

Corporate tax rate of 27% is the nominal tax rate for Advaxis. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ADXS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ADXS are equal to 87.5%.

Life of production assets of 10.5 years is the average useful life of capital assets used in Advaxis operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ADXS is equal to -83.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $54 million for Advaxis - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 41.211 million for Advaxis is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Advaxis at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
AZN AstraZeneca AD 35.44 26.66  sell
ADRO Aduro Biotech 7.30 1.22  str.sell
INO Inovio Pharmac 4.39 0.31  str.sell
MRK Merck&Co 61.28 30.23  sell
SPPI Spectrum Pharm 19.03 0.54  str.sell
CLDX Celldex Therap 2.76 0.31  str.sell
INCY Incyte 93.16 88.49  hold

COMPANY NEWS

▶ ETFs with exposure to Advaxis, Inc. : December 27, 2017   [Dec-27-17 10:57AM  Capital Cube]
▶ 3 Stocks Move on Thursday   [Dec-21-17 02:02PM  GuruFocus.com]
▶ Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today   [Sep-12-17 12:34PM  Motley Fool]
▶ Advaxis reports 3Q loss   [Sep-11-17 09:39PM  Associated Press]
▶ What Does Advaxis Incs (ADXS) Share Price Indicate?   [Sep-08-17 07:20PM  Simply Wall St.]
▶ Advaxis CEO Daniel O'Connor resigns   [Jul-06-17 04:48PM  Reuters]
▶ Advaxis Announces Change in Leadership   [04:30PM  Business Wire]
▶ Advaxis Breaks Down From Key Support Levels   [Jun-16-17 09:58AM  Investopedia]
▶ ETFs with exposure to Advaxis, Inc. : June 15, 2017   [Jun-15-17 12:54PM  Capital Cube]
▶ Advaxis to Webcast Investor & Analyst Day 2017   [Jun-09-17 08:00AM  Business Wire]
▶ Advaxis reports 2Q loss   [05:01AM  Associated Press]
▶ Advaxis to Host Investor & Analyst Day on June 12   [May-18-17 08:00AM  Business Wire]
▶ ETFs with exposure to Advaxis, Inc. : May 4, 2017   [May-04-17 03:37PM  Capital Cube]
▶ ETFs with exposure to Advaxis, Inc. : April 21, 2017   [Apr-21-17 02:42PM  Capital Cube]
▶ Advaxis Appoints Anthony Lombardo as Chief Business Officer   [Apr-19-17 08:00AM  GlobeNewswire]
▶ ETFs with exposure to Advaxis, Inc. : March 27, 2017   [Mar-27-17 03:47PM  Capital Cube]
▶ EMA Certification Paves Way for Advaxis Drug   [Mar-23-17 01:36PM  Investopedia]
▶ EMA Certification Paves Way for Advaxis Drug   [01:36PM  at Investopedia]
▶ Advaxis Inks Cancer Drug Deal with Sellas   [Feb-28-17 10:31AM  at Investopedia]
▶ Advaxis Provides 2017 Business Outlook   [08:00AM  GlobeNewswire]
▶ How Advaxis, Inc. (ADXS) Stacks Up Against Its Peers   [Dec-04-16 03:42PM  at Insider Monkey]
▶ Advaxis Cervical Cancer Drug Makes Progress (ADXS)   [Oct-27-16 02:28PM  at Investopedia]
▶ Advaxis Cervical Cancer Study Continues (ADXS)   [Oct-21-16 01:33PM  at Investopedia]
▶ Advaxis Phase 1/2 Cancer Trial Proceeds (ADXS)   [12:42PM  at Investopedia]
Financial statements of ADXS
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.